| CWGCX | JORAX | CWGCX / JORAX | |
| Total Expense Ratio | 1.49 | 1.02 | 146% |
| Annual Report Gross Expense Ratio | 1.49 | 1.02 | 146% |
| Fund Existence | 25 years | 16 years | - |
| Gain YTD | 22.215 | 18.222 | 122% |
| Front Load | N/A | 6% | - |
| Min. Initial Investment | 250 | 2500 | 10% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 142B | 3.12B | 4,545% |
| Annual Yield % from dividends | 0.75 | 0.76 | 98% |
| Returns for 1 year | 12.16 | 3.75 | 324% |
| Returns for 3 years | 47.61 | 30.22 | 158% |
| Returns for 5 years | 37.45 | 23.70 | 158% |
| Returns for 10 years | 76.13 | 74.38 | 102% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FBTCX | 30.22 | 0.71 | +2.41% |
| Fidelity Advisor Biotechnology C | |||
| AIHHX | 7.37 | 0.08 | +1.10% |
| Aristotle Small/Mid Cap Equity I-2 | |||
| BAFWX | 57.52 | 0.29 | +0.51% |
| Brown Advisory Sustainable Growth I | |||
| CAPAX | 9.35 | 0.04 | +0.43% |
| Federated Hermes Capital Income A | |||
| SCRUX | 12.13 | 0.02 | +0.17% |
| Invesco Income Advantage U.S. Fund R | |||